INP-102, POD-insulin, is a novel potential treatment in development for Alzheimer’s disease and other cognitive disorders by treating metabolic deficiencies in dementia and other cognitive disorders. It is estimated that in 2015, 5.3 million Americans were living with Alzheimer’s disease which is 11% of the population that is over 65 years of age. Given that the population over 65 is projected to increase to 86.7 million by 2050 and that the risk for developing AD increases with age, the number of individuals with AD in 2050 could reach 16 million if no prevention or treatment is discovered.
INP-102 is an intranasal insulin delivered using POD technology. Embracing a promising approach to treating dementia, nose-to-brain insulin addresses the metabolic slowdown observed in the brain of dementia patients. This novel approach has demonstrated improvement of cognition over baseline after 4 months use and sustained improvement after this time. There is minimal systemic exposure after insulin delivery to the upper nasal cavity observed in past clinical studies. Impel is currently engaged in multiple clinical trials (phase 1 – phase 3) with INP-102 and is seeking development and licensing partners to globally commercialize this product.